CytoSorbents Corporation will announce its third quarter 2026 financial results and business updates after market close on November 12, 2026. The company, known for its blood purification technology used in critical care and cardiac surgery, will host a live webcast and Q&A session at 4:30 PM ET the same day. CytoSorbents' lead product, CytoSorb®, is approved in the EU and used globally, while its DrugSorb®-ATR system is under FDA review in the U.S. The webcast will provide insights into the company's progress and regulatory efforts.
CytoSorbents' upcoming Q3 2026 results provide context for health sector activity. For readers following health stocks, 86 of 150 US health-sector stocks rose while 57 fell on Pluang. Notable movers include IOVA at USD 16.12 with an 8.85% gain and 100% sell order activity, BFLY at USD 8.32 up 6.53%, and NUWE at USD 5.87 up 5.48% with 74% sell orders, as of Oct 29, 2026 17:11 WIB.
The inaugural SportsTech Breakthrough Awards recognized leading companies and technologies advancing sports technology globally. Winners span categories like athlete performance, wearables, AI analytics, fan engagement, and smart stadium solutions, h...
The global Industrial Control System (ICS) Security Market is projected to grow from $17.91 billion in 2026 to $38.48 billion by 2031, at a CAGR of 16.5%. This growth is driven by rising cyberattacks targeting critical infrastructure and the increasi...
AdvantageLumber.com has introduced Sketch-A-Deck, a free online software that simplifies deck design for homeowners and contractors. The tool allows users to draw custom deck layouts, attach them to their homes, and generate build-ready plans with de...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
